

Mati Fridkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10623343/publications.pdf>

Version: 2024-02-01

224
papers

8,980
citations

34016

52
h-index

54797

84
g-index

226
all docs

226
docs citations

226
times ranked

6956
citing authors

#	ARTICLE	IF	CITATIONS
1	Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. <i>Nature</i> , 1993, 362, 155-158.	13.7	268
2	Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 773-783.	1.4	263
3	CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. <i>Nature</i> , 1994, 369, 67-71.	13.7	254
4	Bacterial induction of autoantibodies to Î²2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. <i>Journal of Clinical Investigation</i> , 2002, 109, 797-804.	3.9	238
5	Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes. <i>Coordination Chemistry Reviews</i> , 2003, 237, 3-11.	9.5	214
6	Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. <i>Journal of Neurochemistry</i> , 2005, 95, 68-78.	2.1	194
7	Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. <i>Journal of Neurochemistry</i> , 2005, 95, 79-88.	2.1	175
8	Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor Î± Transcriptional Activation by Regulating Nuclear Factor-ÎºB and cAMP Response Element-binding Protein/c-Jun. <i>Journal of Biological Chemistry</i> , 1998, 273, 31427-31436.	1.6	165
9	Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. This manuscript is based on a poster presented at the Brain Research Interactive Symposium on "Neuropeptides at the Millennium", Miami, October 1999.1. <i>Brain Research</i> , 2000, 854, 257-262.	1.1	147
10	Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. <i>Brain Research</i> , 1992, 570, 49-53.	1.1	144
11	Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. <i>Nature Medicine</i> , 1995, 1, 1179-1183.	15.2	143
12	Insulin-like effects of vanadium: basic and clinical implications. <i>Journal of Inorganic Biochemistry</i> , 2000, 80, 21-25.	1.5	142
13	Structure-Function Studies of Polymyxin B Nonapeptide: Implications to Sensitization of Gram-Negative Bacteria#. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3085-3092.	2.9	139
14	Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. <i>FASEB Journal</i> , 2007, 21, 3835-3844.	0.2	131
15	Chirality of Amyloid Suprastructures. <i>Journal of the American Chemical Society</i> , 2008, 130, 4602-4603.	6.6	130
16	Site-Activated Multifunctional Chelator with Acetylcholinesterase and Neuroprotective/Neurorestorative Moieties for Alzheimer's Therapy. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4095-4098.	2.9	129
17	Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator/monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2007, 100, 490-502.	2.1	128
18	The Binding Site of Acetylcholine Receptor as Visualized in the X-Ray Structure of a Complex between Î±-Bungarotoxin and a Mimotope Peptide. <i>Neuron</i> , 2001, 32, 265-275.	3.8	125

#	ARTICLE	IF	CITATIONS
19	Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. <i>Mechanisms of Ageing and Development</i> , 2005, 126, 317-326.	2.2	123
20	NAP, a Femtomolar-Acting Peptide, Protects the Brain Against Ischemic Injury by Reducing Apoptotic Death. <i>Stroke</i> , 2002, 33, 1085-1092.	1.0	120
21	Tuftsins: Its Chemistry, Biology, and Clinical Potentials. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 1989, 24, 1-40.	2.3	110
22	Tuftsins and some analogs. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1977, 496, 203-211.	1.1	108
23	Neurorescue Activity, APP Regulation and Amyloid- β ; Peptide Reduction by Novel Multi-Functional Brain Permeable Iron-Chelating-Antioxidants, M-30 and Green Tea Polyphenol, EGCG. <i>Current Alzheimer Research</i> , 2007, 4, 403-411.	0.7	106
24	Vasoactive Intestinal Peptide Potentiates Sexual Behavior: Inhibition by Novel Antagonist*. <i>Endocrinology</i> , 1989, 125, 2945-2949.	1.4	100
25	Site-Activated Chelators Targeting Acetylcholinesterase and Monoamine Oxidase for Alzheimer's Therapy. <i>ACS Chemical Biology</i> , 2010, 5, 603-610.	1.6	94
26	From Single Target to Multitarget/Network Therapeutics in Alzheimer's Therapy. <i>Pharmaceuticals</i> , 2014, 7, 113-135.	1.7	94
27	From Vasoactive Intestinal Peptide (VIP) Through Activity-Dependent Neuroprotective Protein (ADNP) to NAP: A View of Neuroprotection and Cell Division. <i>Journal of Molecular Neuroscience</i> , 2003, 20, 315-322.	1.1	91
28	New Useful Reagents for Peptide Synthesis. Insoluble Active Esters of Polystyrene-Bound 1-Hydroxybenzotriazole. <i>FEBS Journal</i> , 1975, 59, 55-61.	0.2	88
29	Adhesion of human platelets to serum amyloid A. <i>Blood</i> , 2002, 99, 1224-1229.	0.6	87
30	Use of Polymers as Chemical Reagents. I. Preparation of Peptides. <i>Journal of the American Chemical Society</i> , 1966, 88, 3164-3165.	6.6	85
31	MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. <i>European Journal of Immunology</i> , 1999, 29, 3295-3301.	1.6	79
32	Tuftsins, Thr-Lys-Pro-Arg. <i>Molecular and Cellular Biochemistry</i> , 1981, 41, 73-97.	1.4	78
33	Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. <i>Peptides</i> , 1991, 12, 187-192.	1.2	76
34	The Functional Association of Polymyxin B with Bacterial Lipopolysaccharide Is Stereospecific: Studies on Polymyxin B Nonapeptide. <i>Biochemistry</i> , 2000, 39, 11837-11844.	1.2	75
35	Use of polymers as chemical reagents. II. Synthesis of bradykinin. <i>Journal of the American Chemical Society</i> , 1968, 90, 2953-2957.	6.6	73
36	Tuftsins-macrophage interaction: Specific binding and augmentation of phagocytosis. <i>Journal of Cellular Physiology</i> , 1979, 100, 55-62.	2.0	72

#	ARTICLE	IF	CITATIONS
37	VIP and Peptides Related to Activity-Dependent Neurotrophic Factor Protect PC12 Cells Against Oxidative Stress. <i>Journal of Molecular Neuroscience</i> , 2001, 15, 137-146.	1.1	69
38	Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30. <i>Neurotoxicity Research</i> , 2010, 17, 15-27.	1.3	68
39	From Anti-Parkinson's Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 1-16.	1.2	68
40	Prolonging the Action of Protein and Peptide Drugs by a Novel Approach of Reversible Polyethylene Glycol Modification. <i>Journal of Biological Chemistry</i> , 2004, 279, 38118-38124.	1.6	67
41	Reversible PEGylation: A Novel Technology To Release Native Interferon β over a Prolonged Time Period. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 4897-4904.	2.9	63
42	Modulation of the Hydrophobic Domain of Polymyxin B Nonapeptide: Effect on Outer-Membrane Permeabilization and Lipopolysaccharide Neutralization. <i>Molecular Pharmacology</i> , 2002, 62, 1036-1042.	1.0	62
43	Luteinizing Hormone-Releasing Hormone and Thyrotropin-Releasing Hormone in Human and Bovine Milk. <i>FEBS Journal</i> , 1982, 127, 647-650.	0.2	62
44	On the mechanism of action of the phagocytosis-stimulating peptide tuftsin. <i>Molecular and Cellular Biochemistry</i> , 1980, 30, 71-7.	1.4	60
45	Specific binding sites for the phagocytosis stimulating peptide tuftsin on human polymorphonuclear leukocytes and monocytes. <i>Biochemical and Biophysical Research Communications</i> , 1978, 83, 599-606.	1.0	59
46	A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes. <i>Brain Research</i> , 1991, 540, 319-321.	1.1	59
47	Inhibition of cell adhesion to glycoproteins of the extracellular matrix by peptides corresponding to serum amyloid A. Toward understanding the physiological role of an enigmatic protein. <i>FEBS Journal</i> , 1994, 223, 35-42.	0.2	59
48	Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: Implications for early treatment of Alzheimer's disease. , 1997, 33, 329-342.		59
49	The gonadotropin-releasing hormone family of neuropeptides in the brain of human, bovine and rat: identification of a third isoform. <i>FEBS Letters</i> , 1999, 463, 289-294.	1.3	59
50	Receptor-Mediated Targeting of a Photosensitizer by Its Conjugation to Gonadotropin-Releasing Hormone Analogues. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3965-3974.	2.9	55
51	(4-Hydroxy-3-nitro)benzylated Polystyrene. An Improved Polymeric Nitrophenol Derivative for Peptide Synthesis. <i>FEBS Journal</i> , 1974, 42, 151-156.	0.2	54
52	SH2 Domain-Containing Inositol Polyphosphate 5-Phosphatase Is the Main Mediator of the Inhibitory Action of the Mast Cell Function-Associated Antigen. <i>Journal of Immunology</i> , 2001, 167, 6394-6402.	0.4	54
53	VIP-Related Protection Against Iodoacetate Toxicity in Pheochromocytoma (PC12) Cells: A Model for Ischemic/Hypoxic Injury. <i>Journal of Molecular Neuroscience</i> , 2001, 15, 147-154.	1.1	53
54	Involvement of Pituitary Adenylate Cyclase-Activating Polypeptide II Vasoactive Intestinal Peptide 2 Receptor in Mouse Neocortical Astrocytogenesis. <i>Journal of Neurochemistry</i> , 1998, 70, 2165-2173.	2.1	53

#	ARTICLE	IF	CITATIONS
55	Lipid binding and membrane penetration of polymyxin B derivatives studied in a biomimetic vesicle system. <i>Biochemical Journal</i> , 2003, 375, 405-413.	1.7	53
56	Thiolysis of dinitrophenylimidazoles and its use during synthesis of histidine peptides. <i>Biochemistry</i> , 1970, 9, 5122-5127.	1.2	52
57	Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. <i>Biochemical Pharmacology</i> , 2005, 70, 1642-1652.	2.0	52
58	1-Aminocyclobutanecarboxylic Acid Derivatives as Novel Structural Elements in Bioactive Peptides: Application to Tuftsin Analogs. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 4833-4843.	2.9	51
59	A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo. <i>Journal of Autoimmunity</i> , 2004, 22, 217-225.	3.0	51
60	High levels of vasoactive intestinal peptide in human milk. <i>Biochemical and Biophysical Research Communications</i> , 1985, 133, 228-232.	1.0	49
61	Neurobehavioral Development of Neonatal Mice Following Blockade of VIP During the Early Embryonic Period. <i>Peptides</i> , 1997, 18, 1131-1137.	1.2	49
62	Backbone metal cyclization: Novel ^{99m} Tc labeled GnRH analog as potential SPECT molecular imaging agent in cancer. <i>Nuclear Medicine and Biology</i> , 2004, 31, 921-933.	0.3	48
63	VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2001, 68, 55-64.	1.1	47
64	Design and synthesis of peptides that bind $\hat{\alpha}$ -bungarotoxin with high affinity. <i>Chemistry and Biology</i> , 2001, 8, 147-155.	6.2	46
65	Selective Acetylcholinesterase Inhibitor Activated by Acetylcholinesterase Releases an Active Chelator with Neurorescuing and Anti-Amyloid Activities. <i>ACS Chemical Neuroscience</i> , 2010, 1, 737-746.	1.7	45
66	Relation between Serum Amyloid A Truncated Peptides and Their Suprastructure Chirality. <i>Journal of the American Chemical Society</i> , 2010, 132, 4242-4248.	6.6	45
67	Effect of serum amyloid A on selected in vitro functions of isolated human neutrophils. <i>Translational Research</i> , 1998, 132, 414-420.	2.4	44
68	A Novel Iron-Chelating Derivative of the Neuroprotective Peptide NAPVSIQ Shows Superior Antioxidant and Antineurodegenerative Capabilities. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 126-134.	2.9	42
69	Immunoreactive and biologically active somatostatin in human and sheep milk. <i>FEBS Journal</i> , 1985, 148, 353-357.	0.2	40
70	Binding of C-reactive protein to human neutrophils. <i>FEBS Letters</i> , 1987, 211, 165-168.	1.3	40
71	Novel breast-tumor-associated MUC1-derived peptides: Characterization in Db ^{h2m} $\hat{\alpha}$ - $\hat{\beta}$ 2 microglobulin ($\hat{\beta}$ 2m) null mice transgenic for a chimeric HLA-A2.1/Db ^{h2m} $\hat{\alpha}$ - $\hat{\beta}$ 2 microglobulin single chain. <i>International Journal of Cancer</i> , 2000, 85, 391-397.	2.3	40
72	Reversible PEGylation of peptide YY3-36prolongs its inhibition of food intake in mice. <i>FEBS Letters</i> , 2005, 579, 2439-2444.	1.3	40

#	ARTICLE	IF	CITATIONS
73	Modulation of human neutrophil function by C-reactive protein. FEBS Journal, 1987, 163, 141-146.	0.2	39
74	Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin. FEBS Letters, 1993, 315, 293-297.	1.3	39
75	VIP and the potent analog, stearyl-Nle17 -VIP, induce proliferation of keratinocytes. FEBS Letters, 2000, 475, 78-83.	1.3	39
76	Chemical and Photochemical Electron Transfer of New Helianthrone Derivatives: Aspects of Their Photodynamic Activity. Journal of the American Chemical Society, 2003, 125, 1376-1384.	6.6	38
77	L-Glutamic Acid β -Monohydroxamate. Journal of Biological Chemistry, 1999, 274, 26617-26624.	1.6	37
78	Organic Vanadium Chelators Potentiate Vanadium-Evoked Glucose Metabolism In Vitro and In Vivo: Establishing Criteria for Optimal Chelators. Molecular Pharmacology, 2000, 58, 738-746.	1.0	37
79	Peptide synthesis by means of tert-butyloxycarbonylamino acid derivatives of poly(ethylene-co-N-hydroxymaleimide). Biochemistry, 1972, 11, 466-471.	1.2	36
80	Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. Neuroscience Letters, 2001, 307, 167-170.	1.0	36
81	Successful modulation of murine lupus nephritis with tuftsin-phosphorylcholine. Journal of Autoimmunity, 2015, 59, 1-7.	3.0	36
82	Structural features of luliberin (luteinising hormone-releasing factor) inferred from fluorescence measurements. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1976, 434, 137-143.	1.7	35
83	Self Heat Shock Protein (hsp60) Peptide Serves in a Conjugate Vaccine against a Lethal Pneumococcal Infection. Journal of Infectious Diseases, 1999, 179, 403-413.	1.9	33
84	Serum amyloid A-derived peptides, present in human rheumatic synovial fluids, induce the secretion of interferon- β by human CD4 + T-lymphocytes. FEBS Letters, 2000, 472, 259-262.	1.3	33
85	A Novel Approach for a Water-Soluble Long-Acting Insulin Prodrug: Design, Preparation, and Analysis of [(2-Sulfo)-9-fluorenylmethoxycarbonyl] ³ -insulin. Journal of Medicinal Chemistry, 2000, 43, 2530-2537.	2.9	33
86	A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. Cancer, 2001, 92, 2172-2180.	2.0	33
87	Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus. Journal of Molecular Neuroscience, 1989, 1, 55-61.	1.1	32
88	SYNTHESIS AND BIOLOGICAL ACTIVITY OF TUFTSIN AND OF [O=C-THR¹]TUFTSIN. International Journal of Peptide and Protein Research, 1978, 12, 130-138.	0.1	32
89	New Approaches to Treating Alzheimer's Disease. Perspectives in Medicinal Chemistry, 2015, 7, PMC.S13210.	4.6	32
90	Phosphorylcholine-tuftsin compound prevents development of dextran sulfate-sodium-salt induced murine colitis: Implications for the treatment of human inflammatory bowel disease. Journal of Autoimmunity, 2015, 56, 111-117.	3.0	32

#	ARTICLE	IF	CITATIONS
91	Anti-acetylcholine receptor response achieved by immunization with a synthetic peptide from the receptor sequence. <i>Biochemical and Biophysical Research Communications</i> , 1984, 121, 673-679.	1.0	30
92	Blockade of VIP during Neonatal Development Induces Neuronal Damage and Increases VIP and VIP Receptors in Brain. <i>Annals of the New York Academy of Sciences</i> , 1994, 739, 211-225.	1.8	30
93	Albumin ^α Insulin Conjugate Releasing Insulin Slowly under Physiological Conditions: A New Concept for Long-Acting Insulin. <i>Bioconjugate Chemistry</i> , 2005, 16, 913-920.	1.8	30
94	Site-Activated Chelators Derived from Anti-Parkinson Drug Rasagiline as a Potential Safer and More Effective Approach to the Treatment of Alzheimer's Disease. <i>Neurochemical Research</i> , 2010, 35, 2117-2123.	1.6	30
95	Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms. <i>Regulatory Peptides</i> , 1999, 84, 55-67.	1.9	29
96	Neopeptide Antibiotics That Function as Opsonins and Membrane-Permeabilizing Agents for Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3122-3128.	1.4	28
97	Novel Multifunctional Anti-Alzheimer Drugs with Various CNS Neurotransmitter Targets and Neuroprotective Moieties. <i>Current Alzheimer Research</i> , 2007, 4, 522-536.	0.7	28
98	Turning Low-Molecular-Weight Drugs into Prolonged Acting Prodrugs by Reversible Pegylation: A Study with Gentamicin. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4300-4305.	2.9	27
99	Growth hormone releasing factor-like immunoreactivity in human milk. <i>Biochemical and Biophysical Research Communications</i> , 1986, 135, 1084-1089.	1.0	26
100	Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. <i>Journal of Clinical Immunology</i> , 2000, 20, 187-194.	2.0	26
101	A Vasoactive Intestinal Peptide Antagonist Inhibits the Growth of Glioblastoma Cells. <i>Journal of Molecular Neuroscience</i> , 2001, 17, 331-340.	1.1	26
102	Tufts-in-AZT conjugate: potential macrophage targeting for AIDS therapy. <i>Journal of Peptide Science</i> , 2005, 11, 37-44.	0.8	26
103	Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites. <i>European Journal of Immunology</i> , 1997, 27, 3105-3114.	1.6	25
104	Design and synthesis of peptides that bind α -bungarotoxin with high affinity and mimic the three-dimensional structure of the binding-site of acetylcholine receptor. <i>Biophysical Chemistry</i> , 2002, 100, 293-305.	1.5	25
105	Pneumococcal Capsular Polysaccharide Is Immunogenic When Present on the Surface of Macrophages and Dendritic Cells: TLR4 Signaling Induced by a Conjugate Vaccine or by Lipopolysaccharide Is Conducive. <i>Journal of Immunology</i> , 2008, 180, 2409-2418.	0.4	25
106	Tufts-in-Phosphorylcholine Maintains Normal Gut Microbiota in Collagen Induced Arthritic Mice. <i>Frontiers in Microbiology</i> , 2017, 8, 1222.	1.5	25
107	Detection of mRNAs containing regulatory peptide coding sequences using synthetic oligodeoxynucleotides. <i>Journal of Cellular Biochemistry</i> , 1984, 26, 147-156.	1.2	24
108	Studies toward the biosynthesis of vasoactive intestinal peptide (VIP). <i>Peptides</i> , 1984, 5, 161-166.	1.2	24

#	ARTICLE	IF	CITATIONS
109	Binding of human serum amyloid P component (hSAP) to human neutrophils. FEBS Journal, 1994, 223, 805-811.	0.2	24
110	Generation of Free Radicals by Emodic Acid and its [d-Lys6]GnRH-conjugate. Photochemistry and Photobiology, 2001, 74, 226.	1.3	24
111	In vitro and in vivo treatment of colon cancer by VIP antagonists. Regulatory Peptides, 2002, 109, 127-133.	1.9	23
112	(N-stearyl, Norleucine ¹⁷)VIPhybrid is a Broad Spectrum Vasoactive Intestinal Peptide Receptor Antagonist. Journal of Molecular Neuroscience, 2002, 18, 29-36.	1.1	23
113	Peptides related to the calcium binding domains II and III of calmodulin. International Journal of Peptide and Protein Research, 1986, 28, 289-297.	0.1	23
114	Î2-Glycoprotein-I based peptide regulate endothelial-cells tissue-factor expression via negative regulation of pGSK3Î2 expression and reduces experimental-antiphospholipid-syndrome. Journal of Autoimmunity, 2011, 37, 8-17.	3.0	23
115	Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus. Journal of Molecular Neuroscience, 1989, 1, 55-61.	1.1	22
116	SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival. Peptides, 1999, 20, 629-633.	1.2	22
117	Combined Local Bloodâ€“Brain Barrier Opening and Systemic Methotrexate for the Treatment of Brain Tumors. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 967-976.	2.4	22
118	Helminth-Based Product and the Microbiome of Mice with Lupus. MSystems, 2019, 4, .	1.7	22
119	Antibodies directed against phosphothreonine residues as potent tools for studying protein phosphorylation. FEBS Journal, 1989, 182, 343-348.	0.2	21
120	A VIP hybrid antagonist: From developmental neurobiology to clinical applications. Cellular and Molecular Neurobiology, 1995, 15, 675-687.	1.7	21
121	Single amino acid analogs of a myasthenogenic peptide modulate specific T cell responses and prevent the induction of experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 1998, 85, 78-86.	1.1	21
122	FACILE THIOLYTIC REMOVAL OF THE <i>o</i>â€“NITROPHENYLSULPHENYL AMINOâ€“PROTECTING GROUP. International Journal of Peptide and Protein Research, 1979, 13, 315-319.	0.1	21
123	Towards the Efficiency of Pharmacologically Active Quinoid Compounds: Electron Transfer and Formation of Reactive Oxygen Species. Applied Magnetic Resonance, 2010, 37, 629-648.	0.6	21
124	The Binding Site of Acetylcholine Receptor. Annals of the New York Academy of Sciences, 2003, 998, 93-100.	1.8	20
125	Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. Journal of Peptide Science, 2008, 14, 321-328.	0.8	20
126	Peptide Derived from HIV-1 TAT Protein Destabilizes a Monolayer of Endothelial Cells in an in Vitro Model of the Blood-Brain Barrier and Allows Permeation of High Molecular Weight Proteins. Journal of Biological Chemistry, 2012, 287, 44676-44683.	1.6	20

#	ARTICLE	IF	CITATIONS
127	Tuftsins Receptors. <i>Annals of the New York Academy of Sciences</i> , 1983, 419, 93-106.	1.8	19
128	A new route to polyamino acids containing histidine. <i>Archives of Biochemistry and Biophysics</i> , 1971, 147, 767-771.	1.4	18
129	Tuftsins Analogs for Probing Its Specific Receptor Site on Phagocytic Cells. <i>FEBS Journal</i> , 1982, 125, 631-638.	0.2	18
130	Receptor-mediated endocytosis of tuftsins by macrophage cells. <i>Biochemical and Biophysical Research Communications</i> , 1984, 119, 203-211.	1.0	18
131	Novel naphthoquinonyl derivatives: Potential structural components for the synthesis of cytotoxic peptides. <i>International Journal of Peptide Research and Therapeutics</i> , 1996, 3, 263-274.	0.1	18
132	A PHOTOLABILE PROTECTING GROUP FOR THE PHENOLIC HYDROXYL FUNCTION OF TYROSINE. <i>International Journal of Peptide and Protein Research</i> , 1977, 9, 91-96.	0.1	18
133	An immunoreceptor tyrosine-based inhibitory motif, with serine at site Y-2, binds SH2-domain-containing phosphatases. <i>FEBS Journal</i> , 2000, 267, 703-711.	0.2	17
134	Vanadate restores glucose 6-phosphate in diabetic rats: a mechanism to enhance glucose metabolism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000, 279, E403-E410.	1.8	17
135	VIP-derived sequences modified by N-terminal stearyl moiety induce cell death: the human keratinocyte as a model. <i>FEBS Letters</i> , 2000, 475, 71-77.	1.3	17
136	Reversible Pegylation Prolongs the Hypotensive Effect of Atrial Natriuretic Peptide. <i>Bioconjugate Chemistry</i> , 2008, 19, 342-348.	1.8	17
137	Helminths-based bi-functional molecule, tuftsins-phosphorylcholine (TPC), ameliorates an established murine arthritis. <i>PLoS ONE</i> , 2018, 13, e0200615.	1.1	17
138	Thiolysis of O-2,4-dinitrophenyltyrosines. <i>Archives of Biochemistry and Biophysics</i> , 1977, 178, 517-526.	1.4	16
139	Functionalization of polystyrene. III. Synthesis of polymeric thiol reagents. <i>Journal of Polymer Science: Polymer Chemistry Edition</i> , 1982, 20, 1469-1487.	0.8	16
140	Poly(L-histidyl-L-alanyl-L-glutamic acid). II. Catalysis of p-nitrophenyl acetate hydrolysis. <i>Biopolymers</i> , 1978, 17, 1679-1692.	1.2	15
141	N-[(2-Sulfo-9-fluorenylmethoxycarbonyl)3-gentamicin C1Is a Long-Acting Prodrug Derivative. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 4264-4270.	2.9	15
142	Synthesis and Active Oxygen Generation by New Emodin Derivatives and Their Gonadotropin-Releasing Hormone Conjugates. <i>Bioconjugate Chemistry</i> , 2006, 17, 1008-1016.	1.8	15
143	Conjugates of gonadotropin releasing hormone (GnRH) with carminic acid: Synthesis, generation of reactive oxygen species (ROS) and biological evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 6789-6798.	1.4	15
144	Thiolysis of the 3-nitro-2-pyridinesulfonyl (Npys) protecting group An approach towards a general deprotection scheme in peptide synthesis. <i>International Journal of Peptide and Protein Research</i> , 1990, 35, 545-549.	0.1	15

#	ARTICLE	IF	CITATIONS
145	The phagocytosis stimulating peptide tuftsin: Further look into structure-function relationships. <i>Molecular and Cellular Biochemistry</i> , 1980, 30, 165-70.	1.4	14
146	Tuftsin, Thr-Lys-Pro-Arg. , 1981, , 73-97.		14
147	[5] Generation and use of antibodies to phosphothreonine. <i>Methods in Enzymology</i> , 1991, 201, 44-53.	0.4	14
148	Design, Synthesis, and Evaluation of a Long-Acting, Potent Analogue of Gonadotropin-Releasing Hormone. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 3645-3652.	2.9	14
149	Synthetic peptides from C-reactive protein containing tuftsin-related sequences. <i>Peptides</i> , 1986, 7, 961-968.	1.2	13
150	C-reactive protein decreases protein phosphorylation in stimulated human neutrophils. <i>FEBS Letters</i> , 1988, 237, 173-177.	1.3	13
151	[2-Sulfo-9-fluorenylmethoxycarbonyl]3â€œexendin-4â€œ a long-acting glucose-lowering prodrug. <i>Biochemical and Biophysical Research Communications</i> , 2003, 305, 386-391.	1.0	13
152	The 2,4â€œdinitrophenyl group for protection of hydroxyl function of tyrosine during solidâ€œphase peptide synthesis. <i>International Journal of Peptide and Protein Research</i> , 1995, 45, 116-121.	0.1	13
153	Tuftsin analogs: synthesis, structure-function relationships, and implications for specificity of tuftsin's bioactivity. <i>Journal of Medicinal Chemistry</i> , 1986, 29, 1961-1968.	2.9	12
154	Synthetic Peptides and Their Antibodies in the Analysis of the Acetylcholine Receptor. <i>Annals of the New York Academy of Sciences</i> , 1987, 505, 256-271.	1.8	12
155	Protection against developmental deficiencies by a lipophilic VIP analogue. <i>Neurochemical Research</i> , 1998, 23, 689-693.	1.6	12
156	Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination. <i>Immunology Letters</i> , 1999, 70, 21-28.	1.1	12
157	Binding of human serum amyloid A (hSAA) and its highâ€œdensity lipoprotein₃ complex (hSAAâ€œHDL₃) to human neutrophils. Possible implication to the function of a protein of an unknown physiological role. <i>International Journal of Peptide and Protein Research</i> , 1996, 48, 503-513.	0.1	12
158	Novel Chelators Targeting Cell Cycle Arrest, Acetylcholinesterase, and Monoamine Oxidase for Alzheimer's Therapy. <i>Current Drug Targets</i> , 2012, 13, 1096-1113.	1.0	12
159	Nonaqueous titrimetric determination of active esters of amino acids and peptide derivatives. <i>Analytical Chemistry</i> , 1970, 42, 275-277.	3.2	11
160	Synthesis and bioactivity of fatty acid-conjugated GnRH derivatives. <i>Life Sciences</i> , 1999, 64, 1543-1552.	2.0	11
161	A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes. <i>Life Sciences</i> , 2002, 71, 2543-2552.	2.0	11
162	POLYMERIC 2â€œMERCAPTOPYRIDINE AND 2â€œMERCAPTOâ€œNITROBENZENE DERIVATIVES: New Reagents for Peptide Synthesis. <i>International Journal of Peptide and Protein Research</i> , 1981, 17, 531-538.	0.1	11

#	ARTICLE	IF	CITATIONS
163	Design and Synthesis of Potent Hexapeptide and Heptapeptide Gonadotropin-Releasing Hormone Antagonists by Truncation of a Decapeptide Analogue Sequence. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 2831-2836.	2.9	10
164	Hypericin Derivatives: Substituent Effects on Radical-anion Formation. <i>Photochemistry and Photobiology</i> , 2001, 74, 149.	1.3	10
165	Newly Designed Modifier Prolongs the Action of Short-Lived Peptides and Proteins by Allowing Their Binding to Serum Albumin. <i>Bioconjugate Chemistry</i> , 2012, 23, 1577-1586.	1.8	10
166	Peptide fragments from the tuftsin containing domain of immunoglobulin G synthesis and biological activity. <i>Biochemical and Biophysical Research Communications</i> , 1983, 115, 193-200.	1.0	9
167	Multiple Actions of a Hybrid PACAP Antagonist: Neuronal Cell Killing and Inhibition of Sperm Motility. <i>Annals of the New York Academy of Sciences</i> , 1998, 865, 266-273.	1.8	9
168	Insulin-like Effects of Vanadium; Reviewing In Vivo and In Vitro Studies and Mechanisms of Action. <i>ACS Symposium Series</i> , 1998, , 308-315.	0.5	9
169	Structure-Activity Studies of Reduced-Size Gonadotropin-Releasing Hormone Agonists Derived from the Sequence of an Endothelin Antagonist. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 2824-2830.	2.9	9
170	Peptides derived from human C-reactive protein inhibit the enzymatic activities of human leukocyte elastase and cathepsin G: use of overlapping peptide sequences to identify a unique inhibitor. <i>Chemical Biology and Drug Design</i> , 1998, 51, 282-289.	1.2	9
171	The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase. <i>Regulatory Peptides</i> , 2002, 108, 175-177.	1.9	8
172	Novel extended and branched N-terminal analogs of VIP. <i>Regulatory Peptides</i> , 2006, 137, 42-49.	1.9	8
173	The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2019, 98, 113-121.	3.0	7
174	Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 638128.	1.6	7
175	Synthetic Pathways to Tuftsin and Radioimmunoassay. <i>Annals of the New York Academy of Sciences</i> , 1983, 419, 12-22.	1.8	6
176	The Tuftsin Receptors. , 1986, , 243-280.		6
177	Polytuftsin: A potential precursor for slow release of the phagocytosis stimulating peptide tuftsin. <i>International Journal of Biochemistry & Cell Biology</i> , 1990, 22, 193-195.	0.8	6
178	Mast Cell Adhesion to Extracellular Matrix: Local Effects of Acute Phase Reactants. <i>International Archives of Allergy and Immunology</i> , 1997, 113, 295-296.	0.9	6
179	Serum amyloid A complexed with extracellular matrix induces the secretion of tumor necrosis factor- α by human T-lymphocytes. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 349-355.	0.1	6
180	Design, synthesis, and evaluation of peptides with estrogen-like activity. <i>Biopolymers</i> , 2004, 76, 404-420.	1.2	6

#	ARTICLE	IF	CITATIONS
181	Novel cyclic azo-bridged analogs of gonadotropin-releasing hormone. <i>Journal of Peptide Science</i> , 2006, 12, 106-115.	0.8	6
182	Synthetic peptides derived from the sequence of human C-reactive protein inhibit the enzymatic activities of human leukocyte elastase and human leukocyte cathepsin G. <i>International Journal of Peptide and Protein Research</i> , 1996, 48, 465-476.	0.1	6
183	Tuftsins-THF- β 2 chimeric peptides: potential novel immunomodulators. <i>Immunopharmacology</i> , 1997, 37, 43-52.	2.0	5
184	Cytotoxic peptides: Naphthoquinonyl derivatives of luteinizing hormone-releasing hormone. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 421-427.	0.1	5
185	A Peptide Based on the Sequence of the CDR3 of a Murine Anti-DNA mAb Is a Better Modulator of Experimental SLE Than Its Single Amino Acid-Substituted Analogs. <i>Cellular Immunology</i> , 2000, 205, 52-61.	1.4	5
186	A Peptide Based on the CDR1 of a Pathogenic anti-DNA Antibody is more Efficient than its Analogs in Inhibiting Autoreactive T Cells. <i>Immunobiology</i> , 2000, 202, 383-393.	0.8	5
187	Novel analogs of VIP with multiple C-terminal domains. <i>Peptides</i> , 2007, 28, 1622-1630.	1.2	5
188	Poly(L-histidyl-L-alanyl-L-glutamic acid). I. Synthesis. <i>Biopolymers</i> , 1977, 16, 2265-2279.	1.2	4
189	Conformational changes of poly(L-histidyl-L-alanyl-L-glutamic acid) in solution. Transition pathways and conformational intermediates. <i>Biopolymers</i> , 1979, 18, 981-993.	1.2	4
190	Tuftsins Binding to Various Macrophage Hybridomas. <i>Annals of the New York Academy of Sciences</i> , 1983, 419, 107-113.	1.8	4
191	Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1985, 15, 31-4.	1.1	4
192	Title is missing!. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 349-355.	0.1	4
193	Novel Methyl Helianthrones as Photosensitizers: Synthesis and Biological Evaluation. <i>Photochemistry and Photobiology</i> , 2005, 81, 250.	1.3	4
194	Restrain of bone growth by Estrogen-Mimetic Peptide-1 (EMP-1): A micro-computed tomographic study. <i>Peptides</i> , 2009, 30, 1181-1186.	1.2	4
195	Converting bleomycin into a prodrug that undergoes spontaneous reactivation under physiological conditions. <i>Toxicology and Applied Pharmacology</i> , 2019, 384, 114782.	1.3	4
196	On the Role of Tryptophan in Luteinizing-Hormone-Releasing Hormone (Luliberin). <i>FEBS Journal</i> , 1977, 79, 269-273.	0.2	3
197	Proteolysis of human C-reactive protein by neutrophil-derived lysosomal enzymes generates peptides which modulate neutrophil function: Implication to the anti-inflammatory mechanism. <i>International Journal of Peptide Research and Therapeutics</i> , 1995, 2, 7-16.	0.1	3
198	Polymyxin B and Related Cyclic Peptides Facilitate Leanness and Reduce Fat Mass and Triglyceride Content in Ageing Rats: Potential Prototype Drugs Against Obesity. <i>International Journal of Peptide Research and Therapeutics</i> , 2006, 12, 121-129.	0.9	3

#	ARTICLE	IF	CITATIONS
199	Albumin-EDTA-Vanadium Is a Powerful Anti-Proliferative Agent, Following Entrance into Glioma Cells via Caveolae-Mediated Endocytosis. <i>Pharmaceutics</i> , 2021, 13, 1557.	2.0	3
200	PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP)/VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTOR SUBTYPES IN RAT TISSUES: INVESTIGATION OF RECEPTOR BINDING, A NOVEL VIP RECEPTOR ANTAGONIST AND CHEMICAL CROSS-LINKING . <i>Biomedical Research</i> , 1994, 15, 145-153.	0.3	3
201	Conjugation of Methotrexate-Amino Derivatives to Macromolecules through Carboxylate Moieties Is Superior Over Conventional Linkage to Amino Residues: Chemical, Cell-Free and In Vitro Characterizations. <i>PLoS ONE</i> , 2016, 11, e0158352.	1.1	2
202	Albuminâ€™Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells. <i>Pharmaceutics</i> , 2022, 14, 71.	2.0	2
203	ANTIBODIES TO SYNTHETIC PEPTIDES AS PROBES FOR THE α -SUBUNIT AND FOR THE CHOLINERGIC BINDING SITE OF THE ACETYLCHOLINE RECEPTOR. , 1985, , 273-282.		1
204	Potentiating vanadium-evoked glucose metabolism by novel hydroxamate derivatives. <i>International Journal of Peptide Research and Therapeutics</i> , 2002, 9, 235-254.	0.1	1
205	Generation of Free Radicals by Emodic Acid and its [d-Lys6]GnRH-conjugateâ€™. <i>Photochemistry and Photobiology</i> , 2007, 74, 226-236.	1.3	1
206	Research Spotlight: Establishing the principle of reversibility in peptide/protein and small-molecule therapy. <i>Therapeutic Delivery</i> , 2012, 3, 17-23.	1.2	1
207	MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. , 1999, 29, 3295.		1
208	Intranasal Delivery of Bioactive Peptides or Peptide Analogues Enhances Spatial Memory and Protects Against Cholinergic Deficits. , 2001, , 363-370.		1
209	Degradation of C-reactive protein (CRP) by neutrophil lysosomal enzymes generates peptidic neutrophil modulators. , 1991, , 898-900.		1
210	From Anti-Parkinsonâ€™s Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimerâ€™s Disease. , 2020, , 1-26.		1
211	Title is missing!. <i>International Journal of Peptide Research and Therapeutics</i> , 1997, 4, 157.	0.1	0
212	Inhibition of human leukocyte elastase and cathepsin G by extended peptides and subunits derived from human C-reactive protein. <i>International Journal of Peptide Research and Therapeutics</i> , 1997, 4, 157-166.	0.1	0
213	Cytotoxic Peptides: Naphthoquinonyl Derivatives of Luteinizing Hormone-Releasing Hormone. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 421-427.	0.1	0
214	Tumor-Associated Antigen Peptides as Anti-Metastatic Vaccines. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 323-328.	0.1	0
215	Tumor-associated antigen peptides as anti-metastatic vaccines. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 323-328.	0.1	0
216	Title is missing!. <i>International Journal of Peptide Research and Therapeutics</i> , 1999, 6, 99-108.	0.1	0

#	ARTICLE	IF	CITATIONS
217	A study of extracellular matrix-cell adhesion peptidic epitopes related to human serum amyloid A (SAA). International Journal of Peptide Research and Therapeutics, 1999, 6, 99-108.	0.1	0
218	Potentiating vanadium-evoked glucose metabolism by novel hydroxamate derivatives. International Journal of Peptide Research and Therapeutics, 2002, 9, 235-254.	0.1	0
219	Novel Methyl Helianthrones as Photosensitizers: Synthesis and Biological Evaluation. Photochemistry and Photobiology, 2005, 81, 250-258.	1.3	0
220	Hypericin Derivatives: Substituent Effects on Radical-anion Formation. Photochemistry and Photobiology, 2007, 74, 149-156.	1.3	0
221	The binding site for α -bungarotoxin in the acetylcholine receptor. , 2004, , 19-25.		0
222	The Design, Synthesis, and Biological Evaluation of VIP and VIP Analogs. Neuromethods, 2008, , 1-9.	0.2	0
223	BINDING OF C-REACTIVE PROTEIN AND RELATED PEPTIDES TO NEUTROPHILS. , 1987, , 239-242.		0
224	Preventive Treatment of Alzheimer's Disease. Advances in Behavioral Biology, 1998, , 635-642.	0.2	0